Pharmaceuticals, Biotechnology & Life Sciences

AbbVie’s steady stock, robust dividends, and portfolio expansion strategy show how the biopharma leader balances growth and risk in a volatile market.

Discover how Sartorius AG and NIBRT are creating Dublin’s first global continuous bioprocessing training hub—boosting efficiency, sustainability, and workforce skills.

Explore Bayer AG’s hybrid governance, glyphosate litigation risks, and new oncology approval—insights to sharpen investor strategy and forecast growth.

Merck KGaA refocuses on high‑growth life‑science franchises, prioritizing early‑stage pipelines with strong safety, efficacy, and regulatory traction.

Novo’s rebranding and new AI partnership with Anthropic reveal a bold strategy to speed drug discovery, streamline trials, and stay ahead of generics.

Danaher’s latest quarter shows 8% revenue growth, 32% EBITDA margin, and a new quarterly dividend—highlighting its integrated diagnostics ecosystem and shareholder‑value focus.

Explore how Sanofi’s partnership with Cheplapharm expands its drug pipeline, global manufacturing sites, and regulatory reach—boosting growth and investor confidence.

Explore Eli Lilly’s cardiometabolic breakthroughs—Foundayo, Retatrutide, and EloraTZP—showing 12–14% weight loss, HbA1c drop, and safe GI profiles poised for FDA/EMA approval.

European equity markets eased amid oil‑price jitters, yet the FTSE 100 gained. Eurofins Scientific’s share lift reflects robust demand for life‑science testing amid evolving biotech breakthroughs.

Amgen’s active role at the Morgan Stanley Global Healthcare Conference shows its commitment to biopharma innovation, amid trial setbacks, while highlighting long‑term growth prospects for patients and investors.